Lexicon Pharmaceuticals, Inc.
LXRX
$0.5298
-$0.0021-0.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,479.34% | 884.75% | 792.40% | 1,734.13% | 766.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,479.34% | 884.75% | 792.40% | 1,734.13% | 766.91% |
| Cost of Revenue | 42.43% | 25.43% | 26.41% | 22.90% | 11.66% |
| Gross Profit | 8.40% | -17.50% | -20.25% | -18.57% | -9.66% |
| SG&A Expenses | 17.20% | 45.35% | 72.50% | 113.62% | 134.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.88% | 37.92% | 54.27% | 71.94% | 69.99% |
| Operating Income | -8.52% | -35.02% | -51.93% | -70.01% | -69.03% |
| Income Before Tax | -13.15% | -37.08% | -54.61% | -75.34% | -73.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.15% | -37.08% | -54.61% | -75.34% | -73.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.15% | -37.08% | -54.61% | -75.34% | -73.74% |
| EBIT | -8.52% | -35.02% | -51.93% | -70.01% | -69.03% |
| EBITDA | -8.56% | -35.11% | -52.03% | -70.15% | -69.19% |
| EPS Basic | 19.54% | 0.62% | -13.88% | -31.39% | -29.29% |
| Normalized Basic EPS | 23.22% | 1.35% | -13.04% | -30.44% | -28.29% |
| EPS Diluted | 19.54% | 0.62% | -13.88% | -31.39% | -29.29% |
| Normalized Diluted EPS | 23.22% | 1.35% | -13.04% | -30.44% | -28.29% |
| Average Basic Shares Outstanding | 44.76% | 40.51% | 38.11% | 33.86% | 33.40% |
| Average Diluted Shares Outstanding | 44.76% | 40.51% | 38.11% | 33.86% | 33.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |